دورية أكاديمية
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
| العنوان: | Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study |
|---|---|
| المؤلفون: | Fracchiolla, Nicola Stefano, Sciumè, Mariarita, Papayannidis, Cristina, Vitale, Antonella, Chiaretti, Sabina, Annunziata, Mario, Giglio, Fabio, Salutari, Prassede, Forghieri, Fabio, Lazzarotto, Davide, Lunghi, Monia, Imovilli, Annalisa, Scappini, Barbara, Bonifacio, Massimiliano, Dargenio, Michelina, Gurrieri, Carmela, Todisco, Elisabetta, Defina, Marzia, Del Principe, Maria Ilaria, Zappasodi, Patrizia, Cerrano, Marco, Santoro, Lidia, Tagliaferri, Elena, Barozzi, Enrico, De Roberto, Pasquale, Canzi, Marta, Buzzatti, Elisa, Sartor, Chiara, Passamonti, Francesco, Foà, Robin, Curti, Antonio |
| المساهمون: | Fracchiolla, N, Sciumè, M, Papayannidis, C, Vitale, A, Chiaretti, S, Annunziata, M, Giglio, F, Salutari, P, Forghieri, F, Lazzarotto, D, Lunghi, M, Imovilli, A, Scappini, B, Bonifacio, M, Dargenio, M, Gurrieri, C, Todisco, E, Defina, M, Del Principe, Mi, Zappasodi, P, Cerrano, M, Santoro, L, Tagliaferri, E, Barozzi, E, De Roberto, P, Canzi, M, Buzzatti, E, Sartor, C, Passamonti, F, Foà, R, Curti, A |
| سنة النشر: | 2023 |
| المجموعة: | Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca |
| مصطلحات موضوعية: | acute lymphoblastic leukemia, blinatumomab, immunotherapy, inotuzumab ozogamicin, Settore MED/15 |
| الوصف: | Background: blinatumomab (blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). however, little is known about the outcome after recurrence and re-treatment with immunotherapy. methods: we describe 71 R/R B-ALL patients treated for different relapses with blina and InO. blina was the first treatment in 57 patients and InO in 14. twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD-); after InO, a CR was achieved in 47 patients (82%, 34 MRD-). In the InO/blina group, after InO, 13 cases (93%) reached a CR (6 MRD-); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD-). Twenty-six patients proceeded to allo-HSCT. In the blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after blina was 7.4 months (11.6 vs. 2.7 months in MRD- vs. MRD+, p = 0.03) and after InO, 5.4 months. In the InO/Blina group, the median OS was 9.4 months; the median DFS after InO was 5.1 months and 1.5 months after Blina (8.7 vs. 2.5 months in MRD- vs. MRD+, p = 0.02). With a median follow-up of 16.5 months from the start of immunotherapy, 24 patients (34%) are alive and 16 (22%) are alive in CR. Conclusion: In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/37760592; info:eu-repo/semantics/altIdentifier/wos/WOS:001071337500001; volume:15; issue:18; firstpage:4623; journal:CANCERS; https://hdl.handle.net/2108/340344Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85172778878 |
| DOI: | 10.3390/cancers15184623 |
| الإتاحة: | https://doi.org/10.3390/cancers15184623Test https://hdl.handle.net/2108/340344Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.EB6C2A9E |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers15184623 |
|---|